203 related articles for article (PubMed ID: 32670759)
1. MLH1 Deficiency Induces Cetuximab Resistance in Colon Cancer via Her-2/PI3K/AKT Signaling.
Han Y; Peng Y; Fu Y; Cai C; Guo C; Liu S; Li Y; Chen Y; Shen E; Long K; Wang X; Yu J; Shen H; Zeng S
Adv Sci (Weinh); 2020 Jul; 7(13):2000112. PubMed ID: 32670759
[TBL] [Abstract][Full Text] [Related]
2. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
Iida M; Brand TM; Starr MM; Huppert EJ; Luthar N; Bahrar H; Coan JP; Pearson HE; Salgia R; Wheeler DL
Mol Cancer; 2014 Oct; 13():242. PubMed ID: 25344208
[TBL] [Abstract][Full Text] [Related]
3. Lemur tyrosine kinase-3 (LMTK3) induces chemoresistance to cetuximab in colorectal cancer via the ERK/MAPK pathway.
Wang C; Yang M; Gu X; Gu Y
Bioengineered; 2021 Dec; 12(1):6594-6605. PubMed ID: 34516351
[TBL] [Abstract][Full Text] [Related]
4. miR-302a Inhibits Metastasis and Cetuximab Resistance in Colorectal Cancer by Targeting NFIB and CD44.
Sun L; Fang Y; Wang X; Han Y; Du F; Li C; Hu H; Liu H; Liu Q; Wang J; Liang J; Chen P; Yang H; Nie Y; Wu K; Fan D; Coffey RJ; Lu Y; Zhao X; Wang X
Theranostics; 2019; 9(26):8409-8425. PubMed ID: 31754405
[No Abstract] [Full Text] [Related]
5. Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways.
Liu YF; Feng ZQ; Chu TH; Yi B; Liu J; Yu H; Xue J; Wang YJ; Zhang CZ
Phytomedicine; 2024 Apr; 126():155462. PubMed ID: 38394734
[TBL] [Abstract][Full Text] [Related]
6. Exosomes derived from MDR cells induce cetuximab resistance in CRC via PI3K/AKT signaling‑mediated Sox2 and PD‑L1 expression.
Wei Z; Wang Z; Chai Q; Li Z; Zhang M; Zhang Y; Zhang L; Tang Q; Zhu H; Sui H
Exp Ther Med; 2023 Feb; 25(2):86. PubMed ID: 36741914
[TBL] [Abstract][Full Text] [Related]
7. The dynamic DNA methylation landscape of the
Savio AJ; Mrkonjic M; Lemire M; Gallinger S; Knight JA; Bapat B
Clin Epigenetics; 2017; 9():26. PubMed ID: 28293327
[TBL] [Abstract][Full Text] [Related]
8. Estrogen enhances mismatch repair by induction of MLH1 expression via estrogen receptor-β.
Lu JY; Jin P; Gao W; Wang DZ; Sheng JQ
Oncotarget; 2017 Jun; 8(24):38767-38779. PubMed ID: 28404976
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancer.
Moreira L; Muñoz J; Cuatrecasas M; Quintanilla I; Leoz ML; Carballal S; Ocaña T; López-Cerón M; Pellise M; Castellví-Bel S; Jover R; Andreu M; Carracedo A; Xicola RM; Llor X; Boland CR; Goel A; Castells A; Balaguer F;
Cancer; 2015 May; 121(9):1395-404. PubMed ID: 25557234
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of GLYR1 contributes to microsatellite instability colorectal cancer by targeting p21 via the p38MAPK and PI3K/AKT pathways.
Hu Z; Long T; Ma Y; Zhu J; Gao L; Zhong Y; Wang X; Wang X; Li Z
J Exp Clin Cancer Res; 2020 May; 39(1):76. PubMed ID: 32370786
[TBL] [Abstract][Full Text] [Related]
11. A dual-targeted molecular therapy of PP242 and cetuximab plays an anti-tumor effect through EGFR downstream signaling pathways in colorectal cancer.
Kong L; Zhang Q; Mao J; Cheng L; Shi X; Yu L; Hu J; Yang M; Li L; Liu B; Qian X
J Gastrointest Oncol; 2021 Aug; 12(4):1625-1642. PubMed ID: 34532116
[TBL] [Abstract][Full Text] [Related]
12. Role of the mitogen-activated protein kinase and phosphoinositide 3-kinase/AKT pathways downstream molecules, phosphorylated extracellular signal-regulated kinase, and phosphorylated AKT in colorectal cancer-a tissue microarray-based approach.
Lugli A; Zlobec I; Minoo P; Baker K; Tornillo L; Terracciano L; Jass JR
Hum Pathol; 2006 Aug; 37(8):1022-31. PubMed ID: 16867865
[TBL] [Abstract][Full Text] [Related]
13. Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab.
Iida M; Brand TM; Campbell DA; Starr MM; Luthar N; Traynor AM; Wheeler DL
Cancer Biol Ther; 2013 Jun; 14(6):481-91. PubMed ID: 23760490
[TBL] [Abstract][Full Text] [Related]
14. FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer.
Nakanishi R; Kitao H; Fujinaka Y; Yamashita N; Iimori M; Tokunaga E; Yamashita N; Morita M; Kakeji Y; Maehara Y
Ann Surg Oncol; 2012 Oct; 19(11):3627-35. PubMed ID: 22526901
[TBL] [Abstract][Full Text] [Related]
15. Loss of MLH1 sensitizes colon cancer cells to DNA-PKcs inhibitor KU60648.
Hinrichsen I; Ackermann A; Düding T; Graband A; Filmann N; Plotz G; Zeuzem S; Brieger A
Mol Carcinog; 2017 Jul; 56(7):1816-1824. PubMed ID: 28224663
[TBL] [Abstract][Full Text] [Related]
16. Targeting the PI3K signaling pathway in KRAS mutant colon cancer.
Hong S; Kim S; Kim HY; Kang M; Jang HH; Lee WS
Cancer Med; 2016 Feb; 5(2):248-55. PubMed ID: 26715098
[TBL] [Abstract][Full Text] [Related]
17. MLH1 mediates cytoprotective nucleophagy to resist 5-Fluorouracil-induced cell death in colorectal carcinoma.
Manzoor S; Saber-Ayad M; Maghazachi AA; Hamid Q; Muhammad JS
Neoplasia; 2022 Feb; 24(2):76-85. PubMed ID: 34952246
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
19. Systems analysis identifies potential target genes to overcome cetuximab resistance in colorectal cancer cells.
Park SM; Hwang CY; Cho SH; Lee D; Gong JR; Lee S; Nam S; Cho KH
FEBS J; 2019 Apr; 286(7):1305-1318. PubMed ID: 30719834
[TBL] [Abstract][Full Text] [Related]
20. miR-199b-3p contributes to acquired resistance to cetuximab in colorectal cancer by targeting CRIM1 via Wnt/β-catenin signaling.
Han H; Li Y; Qin W; Wang L; Yin H; Su B; Yuan X
Cancer Cell Int; 2022 Jan; 22(1):42. PubMed ID: 35090460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
